Remsima (infliximab) is a biologic medicine that helps the pain and swelling of arthritis.
It works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Remsima belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.
Remsima is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that has been designed to be identical to an existing biologic medication, but created using a different process.
Remsima is a biosimilar of Remicade. Both medications are known by the same generic name: infliximab. Biosimilars are often cheaper than the original medication.
Remsima is available as an injection (Remsima SC) and as an intravenous infusion (Remsima IV). The injection can be done quickly at home. The infusion is done every 6 to 8 weeks at a specialized infusion clinic.
Some patients start to feel better quickly with Remsima, but in others, it can take a little longer. It's important for people starting this medication to be patient, give it some time, and continue receiving infusions as prescribed by their doctor.
Important Tests and Risks
Watch Canadian rheumatologist Dr. Andy Thompson introduce Remsima in this short video:
Drug Identification Number (DIN)
02511576 (Pre-filled Syringe)
02511584 (Pre-filled Pen)